Physician profile
Risa J Gorin
NPI 1770524274
$3,363.55
in general payments reported to CMS, 2019-2025
25 companies · $1,101 in 2025
The $1,101 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $68.41 · 2021: $50.37 · 2022: $499 · 2023: $391 · 2024: $908 · 2025: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $552.86 | 2019-2025 | |
| Abbvie INC. | $456.25 | 2019-2025 | |
| Galderma Laboratories, L.P. | $317.38 | 2019-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $296.46 | 2022-2025 | Winlevi, Ilumya |
| Journey Medical Corporation | $257.51 | 2022-2025 | |
| Incyte Corporation | $239.22 | 2023-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $217.56 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $148.36 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $131.80 | 2019-2025 | |
| Janssen Biotech, INC. | $117.00 | 2023-2025 | Tremfya |
| Verrica Pharmaceuticals INC. | $113.20 | 2024 | Ycanth |
| Arcutis Biotherapeutics, INC. | $98.97 | 2023-2024 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $80.05 | 2023-2025 | Dupixent |
| Leo Pharma INC. | $63.01 | 2022-2025 | Adbry |
| Dermavant Sciences, INC. | $50.56 | 2023-2024 | Vtama |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $36.83 | 2025 | Vtama |
| Amgen INC. | $33.04 | 2024 | Otezla |
| Allergan, INC. | $31.57 | 2021-2022 | |
| Ucb, INC. | $30.70 | 2021-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $21.03 | 2025 | |
| Genzyme Corporation | $17.58 | 2022 | |
| Aclaris Therapeutics, INC. | $14.79 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.70 | 2023 | Siliq |
| Vyne Pharmaceuticals INC. | $12.93 | 2021 | |
| Almirall LLC | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Risa Gorin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.